Trastuzumab
Trastuzumab - Related Videos
03:46
Butyl-Dependant Hydrophobic Interaction Liquid Chromatography: A Technique to Characterize Antibody-Drug Conjugates Based on Hydrophobic Interactions
0 Views •
2025
This video demonstrates the hydrophobic interaction liquid chromatography-based characterization of antibody-drug conjugates. Using a butyl ligand-based chromatography column, the antibody-drug conjugates are characterized via hydrophobic interactions with the ligand.
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
0 Views •
Cited by 7 •
2016
We describe a simple cell-based bioassay for detecting, quantifying and monitoring the activity of members of the vascular endothelial growth factor family of ligands. The assay uses chimeric receptors expressed in a factor-dependent cell line to provide a semi-quantitative or quantitative assessment of receptor binding and cross-linking by the ligand.
FAQs
Binding to the extracellular domain of HER2 can produce more than simple receptor occupancy. Trastuzumab can inhibit HER2-associated signaling, which may reduce growth-promoting signals within cancer cells. The antibody can also promote receptor internalization, removing HER2 from the cell surface and potentially limiting continued signaling. These complementary actions link its effects to receptor abundance and activity.
Antibody-dependent cellular cytotoxicity, or ADCC, links antibody binding to immune-mediated killing. After trastuzumab occupies HER2 on a cancer cell, immune effector cells can be recruited to recognize the antibody-coated target and damage it. This provides a second route of action beyond suppressing receptor signaling, making immune engagement an important part of its biological activity.
HER2 overexpression can drive cancer progression, so it identifies tumors in which the target is present at biologically important levels. A greater abundance of the receptor may provide more binding sites for trastuzumab and make interference with HER2 signaling more relevant. This relationship connects receptor biology with the rationale for selecting HER2-positive tumors for treatment.
Molecular characterization identifies whether a tumor is HER2-positive before treatment decisions are made. That information connects a measurable tumor feature with a therapy designed to act on HER2, rather than applying the same treatment approach to every cancer. In biology and oncology, this illustrates how tumor biomarkers can support more selective, mechanism-based treatment strategies.
Trastuzumab is used in HER2-positive breast and gastric cancers. Treatment may pair it with chemotherapy or other targeted agents, rather than treating antibody therapy as an isolated intervention. This makes the biological finding of HER2 overexpression actionable across more than one cancer type and places trastuzumab within combination-based treatment strategies.
Cardiac effects are an important treatment-related consideration with trastuzumab, so clinical use includes attention to cardiac monitoring. This safety focus complements assessment of the tumor’s HER2 status and expected treatment rationale. In practice, monitoring helps clinicians account for potential effects beyond the intended cancer-targeting activity while continuing a biomarker-guided therapeutic approach.